Sirio Pharma (300791) — Cash Flow Reinvestment Rate

Latest as of June 2023: 0.78x

Sirio Pharma (300791) has a Cash Flow Reinvestment Rate of 0.78x as of June 2023, reinvesting CN¥79.56 Million (capex CN¥59.65 Million plus investments CN¥19.92 Million) from operating cash flow of CN¥101.61 Million. Explore Sirio Pharma capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.78x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥79.56 Million
Capex + Investments

Operating Cash Flow

CN¥101.61 Million
CNY

Capital Expenditures

CN¥59.65 Million
CNY

Sirio Pharma Cash Flow Reinvestment Rate (2017–2024)

Historical reinvestment intensity for Sirio Pharma across 8 annual periods. Also explore 300791 current and non-current assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Sirio Pharma (2017–2024)

Year-by-year capital reinvestment analysis for Sirio Pharma. For live market cap and broader valuation context, see 300791 market cap overview.

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2024 1.31x CN¥740.12 Million CN¥566.97 Million CN¥412.13 Million ▼ -68.7%
2023 4.17x CN¥1.61 Billion CN¥386.08 Million CN¥451.70 Million ▲ +90.5%
2022 2.19x CN¥973.69 Million CN¥444.86 Million CN¥293.69 Million ▼ -2.0%
2021 2.23x CN¥762.68 Million CN¥341.38 Million CN¥524.68 Million ▲ +72.8%
2020 1.29x CN¥413.14 Million CN¥319.57 Million CN¥223.14 Million ▼ -49.8%
2019 2.58x CN¥596.90 Million CN¥231.60 Million CN¥166.90 Million ▼ -29.4%
2018 3.65x CN¥669.32 Million CN¥183.46 Million CN¥239.32 Million ▼ -69.5%
2017 11.95x CN¥589.82 Million CN¥49.35 Million CN¥159.82 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow